LY3537021
/ Eli Lilly
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
December 02, 2025
A phase 2 randomized, double-blind, placebo-controlled study to evaluate LY3537021 for the treatment of chemotherapy-induced nausea and vomiting in patients with malignant disease.
(ASCO-GI 2026)
- P2 | "Funded by Eli Lilly and Company Clinical Trial Registration Number: NCT07169851 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."
CINV • Clinical • P2 data • Esophageal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor
December 03, 2025
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
(clinicaltrials.gov)
- P2 | N=204 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting
Enrollment open • Chemotherapy-Induced Nausea and Vomiting • Oncology
September 13, 2025
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
(clinicaltrials.gov)
- P2 | N=204 | Not yet recruiting | Sponsor: Eli Lilly and Company
New P2 trial • Chemotherapy-Induced Nausea and Vomiting • Oncology
July 02, 2023
A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves gastrointestinal tolerability of glucagon-like peptide 1 receptor agonist therapy
(EASD 2023)
- P1 | "Supported By Eli Lilly and Company Clinical Trial Registration Number NCT05444569 Background and aims: The contributions of glucose-dependent insulinotropic polypeptide (GIP) receptor activation to the overall benefit of tirzepatide, which activates both the glucagon-like peptide 1 (GLP-1) receptor and the GIP receptor, are incompletely understood...This study evaluated the safety and tolerability profile of LY3537021 (LY) in combination with liraglutide, in order to evaluate potential mitigation of liraglutide-related gastrointestinal (GI) adverse events... These results suggest that long-acting GIP receptor agonism may enable improvement in tolerability to the GI adverse events associated with GLP-1 receptor agonist therapy, which may contribute to the improved clinical benefits noted with long-acting GIP/GLP-1 receptor co-agonism."
Metabolic Disorders
April 10, 2023
A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting
(ADA 2023)
- "Weight loss efficacy has been observed with glucagon-like peptide 1 (GLP-1) and GIP receptor agonist tirzepatide, but weight loss efficacy has also been observed with GLP-1 agonism mixed with GIP antagonism.LY3537021 (LY), a selective, long-acting GIP receptor agonist, was tested in single [SAD, LY vs placebo (PBO)] and multiple ascending doses (MAD, LY vs PBO once weekly for 4 weeks) to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics.In SAD, healthy participants (N=39) had a mean age of 43.5 yrs and mean weight of 74.4 kg. No nausea or vomiting was observed.Repeated dosing of a long-acting GIP receptor agonist, once weekly for 4 weeks, induced weight loss without gastric emptying delay or nausea and vomiting. The results suggest that GIP agonism can contribute to weight loss effects seen with multi-agonist incretins such as tirzepatide."
Hypoglycemia • Metabolic Disorders
March 01, 2023
A Study of LY3537021 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=47 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed
Trial completion
November 23, 2022
A Study of LY3537021 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=60 | Active, not recruiting | Sponsor: Eli Lilly and Company | Recruiting ➔ Active, not recruiting
Enrollment closed
August 19, 2022
A Study of LY3537021 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=60 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting
Enrollment open
July 06, 2022
A Study of LY3537021 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=60 | Not yet recruiting | Sponsor: Eli Lilly and Company
New P1 trial
December 17, 2021
A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
(clinicaltrials.gov)
- P1; N=85; Completed; Sponsor: Eli Lilly and Company; Active, not recruiting ➔ Completed
Clinical • Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
1 to 10
Of
10
Go to page
1